Pfizer CFO Dave Denton to leave for consumer goods role

Pfizer Inc. (NYSE: PFE) announced that Chief Financial Officer Dave Denton will step down from his role and leave the company on August 15 to pursue a position in the consumer goods industry.

Pfizer has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16. The company said it will conduct an internal and external search for a permanent replacement.

Guegan has more than two decades of experience at Pfizer, with roles spanning global financial operations, research and development, and multiple regions. In her current position, she oversees financial operations and reporting for Pfizer's biopharmaceutical business across all therapeutic areas and geographies. She holds a Master in Business degree from Brest Business School and led the integration of Seagen into Pfizer in 2024.

Albert Bourla, Chairman and Chief Executive Officer, said in a statement: "Given Cecile's deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer's finance organization and keep us focused on what matters most — executing our strategy and delivering for patients and shareholders."

Denton said in a statement: "Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward."

The announcement was made based on information as of June 18, 2026, according to a press release from the company.

You May Also Be Interested In

• Orion Digital receives Nasdaq minimum bid price deficiency notice
• Decoy Therapeutics announces up to $21M private placement
• Ascendis Pharma added to Russell 1000 and other indexes